UBS Group Forecasts Strong Price Appreciation for NeuroPace (NASDAQ:NPCE) Stock

NeuroPace (NASDAQ:NPCE) had its target price raised by stock analysts at UBS Group from $18.00 to $22.00 in a report released on Tuesday, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 40.85% from the company’s previous close.

NPCE has been the subject of several other research reports. Leerink Partners reissued an “outperform” rating and issued a $19.00 price objective on shares of NeuroPace in a research note on Wednesday, November 5th. Wells Fargo & Company increased their price target on NeuroPace from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price objective on NeuroPace from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of NeuroPace in a research report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroPace in a research note on Tuesday, December 9th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.50.

NeuroPace Stock Down 1.6%

Shares of NPCE opened at $15.62 on Tuesday. The company has a quick ratio of 3.94, a current ratio of 4.86 and a debt-to-equity ratio of 3.17. The business has a fifty day moving average of $13.29 and a 200 day moving average of $11.16. The company has a market cap of $520.30 million, a PE ratio of -20.55 and a beta of 1.85. NeuroPace has a 52-week low of $7.56 and a 52-week high of $18.98.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.09. The business had revenue of $27.35 million for the quarter, compared to the consensus estimate of $24.64 million. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 136.60%. On average, sell-side analysts expect that NeuroPace will post -1 EPS for the current year.

Institutional Investors Weigh In On NeuroPace

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its position in NeuroPace by 83.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock valued at $27,000 after purchasing an additional 1,118 shares in the last quarter. Legal & General Group Plc lifted its position in shares of NeuroPace by 86.0% during the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock valued at $30,000 after buying an additional 1,239 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of NeuroPace in the 2nd quarter valued at about $35,000. Quarry LP boosted its holdings in shares of NeuroPace by 94.9% in the 3rd quarter. Quarry LP now owns 3,845 shares of the company’s stock valued at $40,000 after buying an additional 1,872 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its position in shares of NeuroPace by 72.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock worth $71,000 after buying an additional 2,668 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.